Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer

Interstitial lung disease (ILD) occurrence and risk factors were investigated in the Japanese non-small-cell lung cancer, post-marketing, large-scale surveillance study, POLARSTAR. All patients with unresectable, recurrent/advanced non-small-cell lung cancer who were treated with erlotinib in Japan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gemma, Akihiko, Kudoh, Shoji, Ando, Masahiko, Ohe, Yuichiro, Nakagawa, Kazuhiko, Johkoh, Takeshi, Yamazaki, Naoya, Arakawa, Hiroaki, Inoue, Yoshikazu, Ebina, Masahito, Kusumoto, Masahiko, Kuwano, Kazuyoshi, Sakai, Fumikazu, Taniguchi, Hiroyuki, Fukuda, Yuh, Seki, Akihiro, Ishii, Tadashi, Fukuoka, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317960/
https://www.ncbi.nlm.nih.gov/pubmed/25287435
http://dx.doi.org/10.1111/cas.12550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317960/
https://www.ncbi.nlm.nih.gov/pubmed/25287435
http://dx.doi.org/10.1111/cas.12550

Ejemplares similares